Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with EGFR G719X/L861Q/S768I
LL Pang, JD Gan, JR Tan, YH Huang, J Liao… - Cancer, 2022 - Wiley Online Library
Background Afatinib is the only currently approved EGFR‐tyrosine kinase inhibitors for
advanced non–small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I …
advanced non–small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I …
Brain distribution of a panel of epidermal growth factor receptor inhibitors using cassette dosing in wild-type and Abcb1/Abcg2-deficient mice
M Kim, JK Laramy, AS Mohammad, S Talele… - Drug Metabolism and …, 2019 - ASPET
Tyrosine kinase inhibitors that target the epidermal growth factor receptor (EGFR) have had
success in treating EGFR-positive tumors, including non–small-cell lung cancer (NSCLC) …
success in treating EGFR-positive tumors, including non–small-cell lung cancer (NSCLC) …
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li, Y Xu… - Bmc Cancer, 2023 - Springer
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
Dacomitinib for advanced non-small cell lung cancer patients harboring major uncommon EGFR alterations: a dual-center, single-arm, ambispective cohort study in …
HS Li, GJ Yang, Y Cai, JL Li, HY Xu, T Zhang… - Frontiers in …, 2022 - frontiersin.org
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
S Wang, J Li - OncoTargets and therapy, 2019 - Taylor & Francis
The discovery that mutations in the EGFR gene are present in up to 50% of patients with
lung adenocarcinoma, and the development of highly efficacious EGFR tyrosine kinase …
lung adenocarcinoma, and the development of highly efficacious EGFR tyrosine kinase …
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
The optimal management of advanced non‐small cell lung cancer (NSCLC) with
noncanonical epidermal growth factor receptor (EGFR) mutations (ie, exon 19 deletion and …
noncanonical epidermal growth factor receptor (EGFR) mutations (ie, exon 19 deletion and …
[HTML][HTML] First-line treatment in EGFR mutant non-small cell lung cancer: is there a best option?
A Bulbul, H Husain - Frontiers in oncology, 2018 - frontiersin.org
First generation or second generation EGFR tyrosine kinase inhibitors are currently the
standard of care for the first-line management of non-small cell lung cancer (NSCLC) …
standard of care for the first-line management of non-small cell lung cancer (NSCLC) …
[HTML][HTML] Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor …
Results We analyzed 422 patients with EGFR-mutated advanced lung adenocarcinoma
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
[HTML][HTML] Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways
AF AlAsmari, N Ali, F AlAsmari, WA AlAnazi… - Saudi Pharmaceutical …, 2020 - Elsevier
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review
Epidermal growth factor receptor (EGFR) is the most common driver gene involved in non
small cell lung cancer (NSCLC) growth, being found in approximately 10–15% of Caucasian …
small cell lung cancer (NSCLC) growth, being found in approximately 10–15% of Caucasian …